Envista vs Dentsply Sirona
NVST and XRAY side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How NVST and XRAY compare
Envista is the larger company, worth 2.0 times as much as Dentsply Sirona ($3.8B against $1.9B).
Envista grew revenue faster over the last twelve months (11.9% versus −0.76% for Dentsply Sirona).
Envista keeps more of each dollar of sales as profit, with a net margin of 3.3% compared with −15.0% at Dentsply Sirona.
Dentsply Sirona pays a dividend yielding 1.7%; Envista does not pay one.
Envista scores higher on the StockData Score (14 against 9 for Dentsply Sirona), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | NVST | XRAY |
|---|---|---|
| Size and price | ||
| Market cap | $3.8B | $1.9B |
| Share price | $23.51 | $9.53 |
| Change, 1 year | 17.7% | −25.9% |
| Change, 5 years | −45.8% | −82.9% |
| Beta (5Y) | 0.97 | 0.90 |
| Employees | 12K | 14K |
| StockData Score | ||
| Total score | 14 (better) | 9 |
| Valuation score | 3 | 3 |
| Growth score | 4 (better) | 0 |
| Performance score | 4 (better) | 2 |
| Health score | 3 (better) | 1 |
| Dividend score | 0 | 3 (better) |
| Valuation | ||
| P/E | 40.5× | – |
| P/S | 1.3× | 0.5× (better) |
| P/B | 1.2× (better) | 1.4× |
| EV/EBITDA | 10.5× (better) | 99.6× |
| P/FCF | 15.2× | 13.3× (better) |
| FCF yield | 6.6% | 7.5% (better) |
| Fair value | $28.11 | $20.33 |
| Margin of safety | 16.4% | 53.1% (better) |
| Growth | ||
| Revenue growth (TTM) | 11.9% (better) | −0.76% |
| Revenue growth, 5Y average | 7.1% (better) | 2.0% |
| Net income growth (TTM) | 76.6% | – |
| EPS growth (TTM) | 81.3% | – |
| EPS growth, 5Y average | 7.0% | – |
| Profitability | ||
| Gross margin | 55.2% (better) | 49.5% |
| Operating margin | 9.6% (better) | −8.5% |
| Net margin | 3.3% (better) | −15.0% |
| FCF margin | 8.7% (better) | 3.9% |
| Return on equity | 3.1% (better) | −33.0% |
| Return on invested capital | 4.0% (better) | −6.7% |
| Financial health | ||
| Debt / equity | 0.47 (better) | 1.65 |
| Net debt / EBITDA | 0.80 (better) | 50.90 |
| Interest coverage | – | −3.4× |
| Current ratio | 2.43 (better) | 1.63 |
| Altman Z-score | 1.73 (better) | 0.56 |
| Piotroski F-score | 7 (better) | 6 |
| Dividends and buybacks | ||
| Dividend yield | – | 1.7% |
| Years of dividend growth | – | 0 |
| Dividend growth, 5Y average | – | 9.9% |
| Buyback yield | 4.5% | – |
| Shareholder yield | 4.5% (better) | 1.7% |
| Ownership | ||
| Held by institutions | 118% | 114% |
| Held by insiders | 0.89% | 0.87% |
| Insider net buying, 12 months | −$510K | $826K (better) |
| Superinvestors holding | 2 | – |
| Short interest, % of float | 7.6% | 12.9% |
Go deeper
- NVST stock overview
- NVST income statement
- NVST valuation and score
- XRAY stock overview
- XRAY income statement
- XRAY valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.